Preliminary experience in external quality control of RT-PCR PML-RARα detection in promyelocytic leukemia
Preliminary experience in external quality control of RT-PCR PML-RARα detection in promyelocytic leukemia
复制标题
早幼粒细胞白血病RT-PCR PML-RARα检测外部质量控制的初步经验
DOI：
10.1038/sj.leu.2401225
复制
发表时间：
1998
期刊：
影响因子：
11.4
通讯作者：
M. Briz
中科院分区：
文献类型：
--
作者：
P. Bolufer;E. Barragán;M. Sanz;G. Martin;R. Bornstein;Dolors Colomer;M. D. Delgado;Marcos González;Isabel Marugán;José Román;M. T. Gomez;E. Anguita;D. Diverio;C. Chomienne;M. Briz
为了使参与西班牙血液肿瘤治疗计划（PETHEMA）LPA-96（旨在治疗急性早幼粒细胞白血病（APL））的医院实验室在PML/RARα RT-PCR检测中获得的结果标准化，将通过逆转录APL患者骨髓样本中的RNA获得的cDNA样本发送至参与实验室。在这项外部质量评估试验的第一年，最多有12个实验室对9个样品进行了检测。对照基因在90%的样品（69个样品中的62个）中得到令人满意的扩增，支持cDNA用作对照样品的充分性。实验室之间PML/RARα检测的一致性为83%，PML/RRα重排类型的结果相似。然而，仍有17%的分歧，归因于低灵敏度或不适当的方法。评估结果强调，需要实施外部质量评估计划，以确保评估结果的标准化。
To standardize the results obtained in PML/RARα RT-PCR detection by laboratories of hospitals involved in the Spanish Program for Treatment of Hematological Malignancies (PETHEMA) LPA-96, designed for the treatment of acute promyelocytic leukemia (APL), cDNA samples obtained by reverse transcription of RNA from bone marrow samples of patients with APL were sent to participating laboratories. During the first year of this external quality assessment trial nine samples were tested by a maximum of 12 laboratories. The control gene was satisfactorily amplified in 90% of the samples (62 of 69 samples), supporting the adequacy of the cDNA to be used as control sample. There was an 83% concordance between laboratories for PML/RARα detection with similar results for the type of PML/RRα rearrangements. However, 17% disagreement still remained, attributable to low sensitivity or inadequacy of methods followed. The results stressed the need for implementation of an external quality assessment scheme to ensure the standardization of the results.